Syndax Pharmaceuticals
SNDX
216 hedge funds and large institutions have $953M invested in Syndax Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 31 funds opening new positions, 86 increasing their positions, 66 reducing their positions, and 32 closing their positions.
30% more repeat investments, than reductions
Existing positions increased: 86 | Existing positions reduced: 66
15% more call options, than puts
Call options by funds: $14.4M | Put options by funds: $12.5M
0.86% more ownership
Funds ownership: 117.37% → 118.22% (+0.86%)
1% less funds holding
Funds holding: 218 → 216 (-2)
3% less first-time investments, than exits
New positions opened: 31 | Existing positions closed: 32
24% less capital invested
Capital invested by funds: $1.25B → $953M (-$302M)
30% less funds holding in top 10
Funds holding in top 10: 10 → 7 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$21.1M |
| 2 |
Goldman Sachs
New York
|
+$20.6M |
| 3 |
Millennium Management
New York
|
+$12.9M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$10.7M |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$9.15M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$25M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$20.7M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
-$18.6M |
| 4 |
TIM
Thornburg Investment Management
Santa Fe,
New Mexico
|
-$16.1M |
| 5 |
Morgan Stanley
New York
|
-$15.8M |
SNDX Hedge Fund Activity: Q2 2025 in Review
216 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Syndax Pharmaceuticals (SNDX) for Q2 2025, worth a combined $953M — down 24% from $1.25B a quarter earlier.
Sellers outnumbered buyers: 32 funds closed out of SNDX and 31 opened new positions — a net loss of 1 holder — while 66 trimmed existing stakes and 86 added.
The largest buyer was BlackRock, adding an estimated $21.1M. The largest seller was Citadel Advisors, cutting an estimated $25M.
- 216 institutional investors held Syndax Pharmaceuticals (SNDX) as of Q2 2025, down from 218 in Q1 2025.
- Funds reported $953M of Syndax Pharmaceuticals stock for Q2 2025, down 24% quarter-over-quarter.
- 31 funds opened new Syndax Pharmaceuticals positions in Q2 2025 and 32 closed out, a net change of -1 holder.
- The largest Syndax Pharmaceuticals buyer in Q2 2025 was BlackRock, an estimated $21.1M added.
- The largest Syndax Pharmaceuticals seller in Q2 2025 was Citadel Advisors, an estimated $25M sold.
Based on aggregated 13F filings for Q2 2025.